Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination
Status:
Completed
Trial end date:
2014-05-20
Target enrollment:
Participant gender:
Summary
GSK961081 is a novel bifunctional molecule that combines muscarinic antagonism and
beta2-agonism in a single molecule and is in development for the treatment of chronic
obstructive pulmonary disease (COPD). This is a randomised, open-label, six-way crossover,
single dose study. This study evaluates the drug delivery and systemic pharmacokinetics of
GSK961081 following concurrent administration of GSK961081 and fluticasone furoate via dry
powder inhaler (DPI) in comparison to GSK961081 DISKUS. There will be six treatment periods
and 7 days washout period in the study. Subjects will attend the unit in the morning for
dosing and will be resident until 12 hours post administration. All subjects will receive six
treatments.